{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:43:04Z","timestamp":1788799384674,"version":"build-2803163510"},"reference-count":125,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Arizona, College of Medicine\u2014Phoenix"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>In heart failure with reduced ejection fraction (HFrEF), cardiogenic edema develops from impaired cardiac function, pathological remodeling, chronic inflammation, endothelial dysfunction, neurohormonal activation, and altered nitric oxide-related pathways. Pre-clinical HFrEF studies have shown that treatment with sodium\u2013glucose cotransporter-2 inhibitors (SGLT-2i) stimulates natriuretic and osmotic\/diuretic effects, improves overall cardiac function, attenuates maladaptive cardiac remodeling, and reduces chronic inflammation, oxidative stress, and endothelial dysfunction. Here, we review the mechanisms and effects of SGLT-2i therapy on cardiogenic edema in various models of HFrEF. Overall, the data presented suggest a high translational importance of these studies, and pre-clinical studies show that SGLT-2i therapy has a marked effect on suppressing the progression of HFrEF through multiple mechanisms, including those that affect the development of cardiogenic edema.<\/jats:p>","DOI":"10.3390\/biomedicines10082016","type":"journal-article","created":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T21:05:51Z","timestamp":1661115951000},"page":"2016","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Suppression of Cardiogenic Edema with Sodium\u2013Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Mechanisms and Insights from Pre-Clinical Studies"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-2210","authenticated-orcid":false,"given":"Ryan D.","family":"Sullivan","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Arizona College of Medicine\u2013Phoenix, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1811-567X","authenticated-orcid":false,"given":"Mariana E.","family":"McCune","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona College of Medicine\u2013Phoenix, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona College of Medicine\u2013Phoenix, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy L.","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona College of Medicine\u2013Phoenix, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-9029","authenticated-orcid":false,"given":"Inna P.","family":"Gladysheva","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona College of Medicine\u2013Phoenix, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of Heart Failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart Disease and Stroke Statistics-2021 Update: A Report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41569-019-0284-0","article-title":"Genetics of Dilated Cardiomyopathy: Practical Implications for Heart Failure Management","volume":"17","author":"Rosenbaum","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/01.CIR.63.3.645","article-title":"Relation of the Renin-Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure","volume":"63","author":"Dzau","year":"1981","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrcardio.2012.191","article-title":"Causes and Treatment of Oedema in Patients with Heart Failure","volume":"10","author":"Clark","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_8","first-page":"e240","article-title":"2013 Accf\/Aha Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10741-014-9438-7","article-title":"Water and Sodium in Heart Failure: A Spotlight on Congestion","volume":"20","author":"Parrinello","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.15420\/cfr.2015.1.2.90","article-title":"Fluid Management in Patients with Chronic Heart Failure","volume":"1","author":"Pellicori","year":"2015","journal-title":"Card. Fail. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/ejhf.417","article-title":"Lung Congestion in Chronic Heart Failure: Haemodynamic, Clinical, and Prognostic Implications","volume":"17","author":"Melenovsky","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jchf.2014.09.003","article-title":"Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure","volume":"3","author":"Mentz","year":"2015","journal-title":"JACC Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/eurheartj\/ehr042","article-title":"Early Dyspnoea Relief in Acute Heart Failure: Prevalence, Association with Mortality, and Effect of Rolofylline in the Protect Study","volume":"32","author":"Metra","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijcard.2018.02.018","article-title":"Wet Is Bad: Residual Congestion Predicts Worse Prognosis in Acute Heart Failure","volume":"258","author":"Aimo","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijcard.2018.01.067","article-title":"Prevalence, Predictors and Clinical Outcome of Residual Congestion in Acute Decompensated Heart Failure","volume":"258","author":"Demissei","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10741-019-09868-0","article-title":"Congestion Occurrence and Evaluation in Acute Heart Failure Scenario: Time to Reconsider Different Pathways of Volume Overload","volume":"25","author":"Palazzuoli","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.hfc.2021.05.003","article-title":"Congestion in Patients with Advanced Heart Failure: Assessment and Treatment","volume":"17","author":"Lombardi","year":"2021","journal-title":"Heart Fail. Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e007132","DOI":"10.1161\/CIRCHEARTFAILURE.120.007132","article-title":"Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk","volume":"13","author":"Greene","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/eurjhf\/hfs007","article-title":"Clinical Course and Predictive Value of Liver Function Tests in Patients Hospitalized for Worsening Heart Failure with Reduced Ejection Fraction: An Analysis of the Everest Trial","volume":"14","author":"Ambrosy","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41569-020-0379-7","article-title":"Congestion in Heart Failure: A Contemporary Look at Physiology, Diagnosis and Treatment","volume":"17","author":"Boorsma","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Acute Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure, I. Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/CIRCHEARTFAILURE.114.001957","article-title":"Relief and Recurrence of Congestion During and after Hospitalization for Acute Heart Failure: Insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (Dose-Ahf) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (Caress-Hf)","volume":"8","author":"Lala","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1161\/CIRCULATIONAHA.119.039920","article-title":"Prognostic Implications of Congestion on Physical Examination among Contemporary Patients with Heart Failure and Reduced Ejection Fraction: Paradigm-Hf","volume":"140","author":"Selvaraj","year":"2019","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e002922","DOI":"10.1161\/CIRCHEARTFAILURE.115.002922","article-title":"Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed","volume":"9","author":"Miller","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(18)31808-7","article-title":"Heart Failure Drug Treatment","volume":"393","author":"Rossignol","year":"2019","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sullivan, R.D., Mehta, R.M., Tripathi, R., Reed, G.L., and Gladysheva, I.P. (2019). Renin Activity in Heart Failure with Reduced Systolic Function-New Insights. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133182"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart Failure with Reduced Ejection Fraction: A Review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10741-019-09829-7","article-title":"New Perspectives and Future Directions in the Treatment of Heart Failure","volume":"25","author":"Pellicori","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 Esc Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.21037\/atm-20-4640","article-title":"Updates in Pharmacotherapy of Heart Failure with Reduced Ejection Fraction","volume":"9","author":"Espinoza","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jchf.2020.12.014","article-title":"Transitioning Hfref Patients on Ace Inhibitors to Modern Medical Therapy: What Is the Next Step?","volume":"9","author":"Patel","year":"2021","journal-title":"JACC Heart Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2147\/TCRM.S275076","article-title":"The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence","volume":"17","author":"Gupta","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The Sglt2 Inhibitor Canagliflozin in Heart Failure: The Chief-Hf Remote, Patient-Centered Randomized Trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Hernandez, M., Sullivan, R.D., McCune, M.E., Reed, G.L., and Gladysheva, I.P. (2022). Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion. Diagnostics, 12.","DOI":"10.3390\/diagnostics12040989"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10741-019-09881-3","article-title":"Role of Endothelial Dysfunction in Heart Failure","volume":"25","author":"Zuchi","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in Heart Failure: Jacc State-of-the-Art Review","volume":"75","author":"Murphy","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1152\/physrev.1971.51.3.527","article-title":"Interstitial Fluid Pressure","volume":"51","author":"Guyton","year":"1971","journal-title":"Physiol. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jacc.2021.05.021","article-title":"Pathophysiology of the Lymphatic System in Patients with Heart Failure: Jacc State-of-the-Art Review","volume":"78","author":"Itkin","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"933384","DOI":"10.3389\/fcvm.2022.933384","article-title":"The Interstitial Comartment as a Therapeutic Target in Heart Failure","volume":"9","author":"Aronson","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why Do Sglt2 Inhibitors Reduce Heart Failure Hospitalization? A Differential Volume Regulation Hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Yu, H., Basu, S., and Hallow, K.M. (2020). Cardiac and Renal Function Interactions in Heart Failure with Reduced Ejection Fraction: A Mathematical Modeling Analysis. PLoS Comput. Biol., 16.","DOI":"10.1371\/journal.pcbi.1008074"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Fujiki, S., Tanaka, A., Imai, T., Shimabukuro, M., Uehara, H., Nakamura, I., Matsunaga, K., Suzuki, M., Kashimura, T., and Minamino, T. (Clin. Res. Cardiol., 2022). Body Fluid Regulation Via Chronic Inhibition of Sodium-Glucose Cotransporter-2 in Patients with Heart Failure: A Post Hoc Analysis of the Candle Trial, Clin. Res. Cardiol., online ahead of print.","DOI":"10.1007\/s00392-022-02049-4"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12933-021-01295-6","article-title":"Reduction of Estimated Fluid Volumes Following Initiation of Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease: A Secondary Analysis of the Placebo-Controlled, Randomized Emblem Trial","volume":"20","author":"Tanaka","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1002\/ehf2.13483","article-title":"Sodium-Glucose Cotransporter 2 Inhibitor Effects on Heart Failure Hospitalization and Cardiac Function: Systematic Review","volume":"8","author":"Rasalam","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","article-title":"Physiology of Renal Glucose Handling Via Sglt1, Sglt2 and Glut2","volume":"61","author":"Ghezzi","year":"2018","journal-title":"Diabetologia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-8587(17)30314-5","article-title":"Sglt2 Inhibitors: Hypotheses on the Mechanism of Cardiovascular Protection","volume":"6","author":"Bell","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11886-019-1219-4","article-title":"Mechanisms and Evidence for Heart Failure Benefits from Sglt2 Inhibitors","volume":"21","author":"Wojcik","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"60","DOI":"10.14740\/cr1221","article-title":"A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure","volume":"12","author":"Nightingale","year":"2021","journal-title":"Cardiol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10741-020-10038-w","article-title":"Sglt2-Inhibitors. More Than Just Glycosuria and Diuresis","volume":"26","author":"Fathi","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccl.2013.09.002","article-title":"The Renin-Angiotensin-Aldosterone System and Heart Failure","volume":"32","author":"Sayer","year":"2014","journal-title":"Cardiol. Clin."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","article-title":"Left Ventricular Remodeling in Heart Failure: Current Concepts in Clinical Significance and Assessment","volume":"4","author":"Konstam","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCHEARTFAILURE.109.895581","article-title":"Decompensated Heart Failure Is Associated with Reduced Corin Levels and Decreased Cleavage of Pro-Atrial Natriuretic Peptide","volume":"4","author":"Ibebuogu","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/HYPERTENSIONAHA.115.06300","article-title":"Depressed Corin Levels Indicate Early Systolic Dysfunction before Increases of Atrial Natriuretic Peptide\/B-Type Natriuretic Peptide and Heart Failure Development","volume":"67","author":"Tripathi","year":"2016","journal-title":"Hypertension"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7279036","DOI":"10.1155\/2018\/7279036","article-title":"Possible Enzymatic Downregulation of the Natriuretic Peptide System in Patients with Reduced Systolic Function and Heart Failure: A Pilot Study","volume":"2018","author":"Zaidi","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM199908193410806","article-title":"Hormones and Hemodynamics in Heart Failure","volume":"341","author":"Schrier","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Sullivan, R.D., Mehta, R.M., Tripathi, R., Gladysheva, I.P., and Reed, G.L. (2019). Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20163886"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"910100","DOI":"10.3389\/fcvm.2022.910100","article-title":"Biomarkers of Volume Overload and Edema in Heart Failure with Reduced Ejection Fraction","volume":"9","author":"Chiorescu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/61.suppl_2.S4","article-title":"Pathophysiologic Role of the Renin-Angiotensin-Aldosterone and Sympathetic Nervous Systems in Heart Failure","volume":"61","author":"Adams","year":"2004","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal Activation in Heart Failure with Reduced Ejection Fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ansary, T.M., Nakano, D., and Nishiyama, A. (2019). Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030629"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics","volume":"73","author":"Ishikawa","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4330\/wjc.v12.i8.373","article-title":"Sympathetic Nervous System Activation and Heart Failure: Current State of Evidence and the Pathophysiology in the Light of Novel Biomarkers","volume":"12","author":"Borovac","year":"2020","journal-title":"World J. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: The Embody Trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/01.CIR.88.3.1004","article-title":"Natriuretic Peptide System in Human Heart Failure","volume":"88","author":"Wei","year":"1993","journal-title":"Circulation"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"650124","DOI":"10.3389\/fphys.2021.650124","article-title":"Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure","volume":"12","author":"Gidlof","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11010-017-3018-9","article-title":"Effect of Empagliflozin on Cardiac Biomarkers in a Zebrafish Model of Heart Failure: Clues to the Empa-Reg Outcome Trial?","volume":"433","author":"Shi","year":"2017","journal-title":"Mol. Cell. Biochem."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Tripathi, R., Sullivan, R.D., Fan, T.M., Houng, A.K., Mehta, R.M., Reed, G.L., and Gladysheva, I.P. (2020). Cardiac-Specific Overexpression of Catalytically Inactive Corin Reduces Edema, Contractile Dysfunction, and Death in Mice with Dilated Cardiomyopathy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010203"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vascn.2019.02.001","article-title":"A Mouse Model of Heart Failure Exhibiting Pulmonary Edema and Pleural Effusion: Useful for Testing New Drugs","volume":"96","author":"Ma","year":"2019","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Tripathi, R., Sullivan, R.D., Fan, T.M., Mehta, R.M., Gladysheva, I.P., and Reed, G.L. (2021). A Low-Sodium Diet Boosts Ang (1-7) Production and No-Cgmp Bioavailability to Reduce Edema and Enhance Survival in Experimental Heart Failure. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084035"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","article-title":"The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Attenuates Cardiac Fibrosis and Improves Ventricular Hemodynamics in Hypertensive Heart Failure Rats","volume":"18","author":"Lee","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/dom.13536","article-title":"Empagliflozin Reduces Myocardial Ketone Utilization While Preserving Glucose Utilization in Diabetic Hypertensive Heart Disease: A Hyperpolarized (13) C Magnetic Resonance Spectroscopy Study","volume":"21","author":"Abdurrachim","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-Glucose Co-Transporter 2 Inhibition with Empagliflozin Improves Cardiac Function in Non-Diabetic Rats with Left Ventricular Dysfunction after Myocardial Infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e006277","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin Blunts Worsening Cardiac Dysfunction Associated with Reduced Nlrp3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/JOE-17-0457","article-title":"Cardioprotection of Dapagliflozin and Vildagliptin in Rats with Cardiac Ischemia-Reperfusion Injury","volume":"236","author":"Tanajak","year":"2018","journal-title":"J Endocrinol"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12933-020-0994-y","article-title":"Load-Independent Effects of Empagliflozin Contribute to Improved Cardiac Function in Experimental Heart Failure with Reduced Ejection Fraction","volume":"19","author":"Connelly","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute Canagliflozin Treatment Protects against in Vivo Myocardial Ischemia-Reperfusion Injury in Non-Diabetic Male Rats and Enhances Endothelium-Dependent Vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Wang, K., Li, Z., Sun, Y., Liu, X., Ma, W., Ding, Y., Hong, J., Qian, L., and Xu, D. (J. Cardiovasc. Transl. Res., 2021). Dapagliflozin Improves Cardiac Function, Remodeling, Myocardial Apoptosis, and Inflammatory Cytokines in Mice with Myocardial Infarction, J. Cardiovasc. Transl. Res., (online ahead of print).","DOI":"10.1007\/s12265-021-10192-y"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis\/Stiffness in Nondiabetic Heart Failure: A Multimodality Study","volume":"14","author":"Ishikawa","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Attenuates Diabetic Cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"14061","DOI":"10.1038\/s41598-020-70708-5","article-title":"Effects of Empagliflozin and Target-Organ Damage in a Novel Rodent Model of Heart Failure Induced by Combined Hypertension and Diabetes","volume":"10","author":"Kraker","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-020-01040-5","article-title":"Empagliflozin Prevents Doxorubicin-Induced Myocardial Dysfunction","volume":"19","author":"Sabatino","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e018298","DOI":"10.1161\/JAHA.120.018298","article-title":"Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure","volume":"10","author":"Li","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"105788","DOI":"10.1016\/j.ejps.2021.105788","article-title":"Empagliflozin Prevents from Early Cardiac Injury Post Myocardial Infarction in Non-Diabetic Mice","volume":"161","author":"Liu","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"13553","DOI":"10.1038\/s41598-020-70454-8","article-title":"Empagliflozin Improves Post-Infarction Cardiac Remodeling through Gtp Enzyme Cyclohydrolase 1 and Irrespective of Diabetes Status","volume":"10","author":"Lax","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e13741","DOI":"10.14814\/phy2.13741","article-title":"Empagliflozin Normalizes the Size and Number of Mitochondria and Prevents Reduction in Mitochondrial Size after Myocardial Infarction in Diabetic Hearts","volume":"6","author":"Mizuno","year":"2018","journal-title":"Physiol. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"104870","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin Protects Heart from Inflammation and Energy Depletion Via Ampk Activation","volume":"158","author":"Koyani","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1536\/ihj.18-392","article-title":"Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet","volume":"60","author":"Kimura","year":"2019","journal-title":"Int. Heart J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000501081","article-title":"A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion","volume":"44","author":"Kuriyama","year":"2019","journal-title":"Kidney Blood Press. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.biopha.2018.10.095","article-title":"Early Administration of Empagliflozin Preserved Heart Function in Cardiorenal Syndrome in Rat","volume":"109","author":"Yang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus with That of Heart Failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium\/Glucose Cotransporter 2 Inhibitor Empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1517\/14728222.6.3.291","article-title":"Targeting the Myocardial Sodium-Hydrogen Exchange for Treatment of Heart Failure","volume":"6","author":"Morris","year":"2002","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1093\/cvr\/cvab129","article-title":"Sglt2 Inhibitor Empagliflozin Inhibits the Cardiac Na+\/H+ Exchanger 1: Persistent Inhibition under Various Experimental Conditions","volume":"117","author":"Zuurbier","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/bjp.2008.189","article-title":"Chronic Inhibition of the Na+\/H+\u2014Exchanger Causes Regression of Hypertrophy, Heart Failure, and Ionic and Electrophysiological Remodelling","volume":"154","author":"Baartscheer","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jacbts.2019.07.010","article-title":"Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure with Reduced Ejection Fraction with or without Diabetes","volume":"4","author":"Yurista","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","article-title":"Off-Target Effects of Sglt2 Blockers: Empagliflozin Does Not Inhibit Na+\/H+ Exchanger-1 or Lower [Na+]i in the Heart","volume":"117","author":"Chung","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1093\/cvr\/cvab184","article-title":"Sglt2 Inhibitors and the Cardiac Na+\/H+ Exchanger-1: The Plot Thickens","volume":"117","author":"Chung","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1113\/jphysiol.2011.206136","article-title":"Pathophysiology of Tissue Fluid Accumulation in Inflammation","volume":"589","author":"Wiig","year":"2011","journal-title":"J Physiol"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11897-017-0337-9","article-title":"Inflammation\u2014Cause or Consequence of Heart Failure or Both?","volume":"14","author":"Tschope","year":"2017","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/2047487319870344","article-title":"Oxidative Stress and Inflammation in the Evolution of Heart Failure: From Pathophysiology to Therapeutic Strategies","volume":"27","author":"Aimo","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1152\/physrev.00012.2005","article-title":"Signaling Mechanisms Regulating Endothelial Permeability","volume":"86","author":"Mehta","year":"2006","journal-title":"Physiol. Rev."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","article-title":"Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: Jacc Review Topic of the Week","volume":"76","author":"Emdin","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/eurheartj\/ehi001","article-title":"Endothelial Dysfunction in Patients with Chronic Heart Failure Is Independently Associated with Increased Incidence of Hospitalization, Cardiac Transplantation, or Death","volume":"26","author":"Fischer","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/CIRCRESAHA.109.210542","article-title":"Lung Endothelial Dysfunction in Congestive Heart Failure: Role of Impaired Ca2+ Signaling and Cytoskeletal Reorganization","volume":"106","author":"Kerem","year":"2010","journal-title":"Circ. Res."},{"key":"ref_105","first-page":"2048004019843047","article-title":"Endothelial Dysfunction and Heart Failure: A Review of the Existing Bibliography with Emphasis on Flow Mediated Dilation","volume":"8","author":"Giannitsi","year":"2019","journal-title":"JRSM Cardiovasc. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13300-020-00885-z","article-title":"Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies","volume":"11","author":"Alshnbari","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"107832","DOI":"10.1016\/j.pharmthera.2021.107832","article-title":"Endothelial Function and Dysfunction: Impact of Sodium-Glucose Cotransporter 2 Inhibitors","volume":"224","author":"Ugusman","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.kint.2021.01.008","article-title":"Reversing Endothelial Dysfunction with Empagliflozin to Improve Cardiomyocyte Function in Cardiorenal Syndrome","volume":"99","author":"Dou","year":"2021","journal-title":"Kidney Int."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.kint.2020.12.013","article-title":"Empagliflozin Restores Chronic Kidney Disease-Induced Impairment of Endothelial Regulation of Cardiomyocyte Relaxation and Contraction","volume":"99","author":"Juni","year":"2021","journal-title":"Kidney Int."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"L1027","DOI":"10.1152\/ajplung.00167.2015","article-title":"Sglt Inhibitors Attenuate No-Dependent Vascular Relaxation in the Pulmonary Artery but Not in the Coronary Artery","volume":"309","author":"Han","year":"2015","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"9549036","DOI":"10.1155\/2016\/9549036","article-title":"A New Transgenic Mouse Model of Heart Failure and Cardiac Cachexia Raised by Sustained Activation of Met Tyrosine Kinase in the Heart","volume":"2016","author":"Sala","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of Sglt2 (Sodium-Glucose Cotransporter 2) Inhibitors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the Empa-Reg Outcome Study? A Unifying Hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e019995","DOI":"10.1161\/JAHA.120.019995","article-title":"Effects of Sodium-Glucose Linked Transporter 2 Inhibition with Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice","volume":"10","author":"Croteau","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.crphys.2022.05.003","article-title":"Empagliflozin Restores Cardiac Metabolic Flexibility in Diet-Induced Obese C57bl6\/J Mice","volume":"5","author":"Xie","year":"2022","journal-title":"Curr. Res. Physiol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Sullivan, R.D., Houng, A.K., Gladysheva, I.P., Fan, T.M., Tripathi, R., Reed, G.L., and Wang, D. (2020). Corin Overexpression Reduces Myocardial Infarct Size and Modulates Cardiomyocyte Apoptotic Cell Death. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103456"},{"key":"ref_117","unstructured":"Reed, G.L., Gladysheva, I.P., Sullivan, R.D., and Mehta, R.M. (2021). Method of Personalized Treatment for Cardiomyopathy and Heart Failure and Associated Diseases by Measuring Edema and Cachexia\/Sarcopenia. (17\/313,904, 20210263120), United States Patent Application Serial Number."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.61.3.299","article-title":"Nutritional Edema in the Dog: I. Development of Hypoproteinemia on a Diet Deficient in Protein","volume":"61","author":"Weech","year":"1935","journal-title":"J. Exp. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1113\/EP089037","article-title":"Prone Positioning Redistributes Gravitational Stress in the Lung in Normal Conditions and in Simulations of Oedema","volume":"107","author":"Holverda","year":"2022","journal-title":"Exp. Physiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1469-185X.1985.tb00713.x","article-title":"Evolution of Cardiovascular Baroreceptor Control","volume":"60","author":"Bagshaw","year":"1985","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/cc4840","article-title":"Lung and \u2018End Organ\u2019 Injury Due to Mechanical Ventilation in Animals: Comparison between the Prone and Supine Positions","volume":"10","author":"Nakos","year":"2006","journal-title":"Crit. Care"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"C272","DOI":"10.1093\/eurheartj\/suac017","article-title":"Anmco Statement on the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure: A Practical Guide for a Streamlined Implementation","volume":"24","author":"Gronda","year":"2022","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_123","first-page":"45","article-title":"Risks Vs Benefits for Sglt2 Inhibitor Medications","volume":"35","author":"Pittampalli","year":"2018","journal-title":"Fed. Pract."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/ehf2.13169","article-title":"Efficacy and Safety of Sglt2 Inhibitors in Heart Failure: Systematic Review and Meta-Analysis","volume":"7","author":"Butler","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2042098621989134","DOI":"10.1177\/2042098621989134","article-title":"Adverse Events Associated with Sodium Glucose Co-Transporter 2 Inhibitors: An Overview of Quantitative Systematic Reviews","volume":"12","author":"Pelletier","year":"2021","journal-title":"Ther. Adv. Drug Saf."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/8\/2016\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:12:12Z","timestamp":1760141532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/8\/2016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":125,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["biomedicines10082016"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10082016","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]}}}